Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klümpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA; FOENIX-CCA2 Study Investigators. Goyal L, et al. Among authors: abrams ta. N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834. N Engl J Med. 2023. PMID: 36652354 Clinical Trial.
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX. Goyal L, et al. Among authors: abrams ta. Cancer. 2017 Jun 1;123(11):1979-1988. doi: 10.1002/cncr.30571. Epub 2017 Feb 13. Cancer. 2017. PMID: 28192597 Free PMC article. Clinical Trial.
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer.
Goyal L, Chaudhary SP, Kwak EL, Abrams TA, Carpenter AN, Wolpin BM, Wadlow RC, Allen JN, Heist R, McCleary NJ, Chan JA, Goessling W, Schrag D, Ng K, Enzinger PC, Ryan DP, Clark JW. Goyal L, et al. Among authors: abrams ta. Invest New Drugs. 2020 Oct;38(5):1533-1539. doi: 10.1007/s10637-019-00889-y. Epub 2020 Jan 2. Invest New Drugs. 2020. PMID: 31898183 Clinical Trial.
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.
Cleary JM, Raghavan S, Wu Q, Li YY, Spurr LF, Gupta HV, Rubinson DA, Fetter IJ, Hornick JL, Nowak JA, Siravegna G, Goyal L, Shi L, Brais LK, Loftus M, Shinagare AB, Abrams TA, Clancy TE, Wang J, Patel AK, Brichory F, Vaslin Chessex A, Sullivan RJ, Keller RB, Denning S, Hill ER, Shapiro GI, Pokorska-Bocci A, Zanna C, Ng K, Schrag D, Jänne PA, Hahn WC, Cherniack AD, Corcoran RB, Meyerson M, Daina A, Zoete V, Bardeesy N, Wolpin BM. Cleary JM, et al. Among authors: abrams ta. Cancer Discov. 2021 Oct;11(10):2488-2505. doi: 10.1158/2159-8290.CD-20-1669. Epub 2021 Apr 29. Cancer Discov. 2021. PMID: 33926920 Free PMC article.
A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.
Kulke MH, Chan JA, Meyerhardt JA, Zhu AX, Abrams TA, Blaszkowsky LS, Regan E, Sidor C, Fuchs CS. Kulke MH, et al. Among authors: abrams ta. Cancer Chemother Pharmacol. 2011 Aug;68(2):293-300. doi: 10.1007/s00280-010-1478-7. Epub 2010 Oct 20. Cancer Chemother Pharmacol. 2011. PMID: 20960192 Free PMC article. Clinical Trial.
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.
Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP. Zhu AX, et al. Among authors: abrams ta. Cancer. 2011 Nov 15;117(22):5094-102. doi: 10.1002/cncr.26165. Epub 2011 Apr 27. Cancer. 2011. PMID: 21538343 Free PMC article. Clinical Trial.
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer.
Faris JE, Arnott J, Zheng H, Ryan DP, Abrams TA, Blaszkowsky LS, Clark JW, Enzinger PC, Hezel AF, Ng K, Wolpin BM, Kwak EL. Faris JE, et al. Among authors: abrams ta. Invest New Drugs. 2012 Aug;30(4):1614-20. doi: 10.1007/s10637-011-9708-3. Epub 2011 Jul 29. Invest New Drugs. 2012. PMID: 21800081 Free PMC article. Clinical Trial.
75 results